UK, EU & US GMP/GDP Regulatory Update | Edition 31
GMP and GDP regulatory update covering product quality, medicine shortages, supply-chain integrity, inspection awareness and audit readiness.
GXP COMPLIANCE NEWSLETTER
Kyle Winn and Adam Walker
6/2/202610 min read
Help Me GxP
Prepared for publication: 2 June 2026
Source window: 12 May to 2 June 2026
Focus: UK, EU and United States GMP / GDP
INTRODUCTION
After a short pause while the app and podcast work took priority, the newsletter is back under the Help Me GxP banner.
The scope has now moved beyond GMP alone.
This edition looks at GxP through two practical lenses:
GMP: how medicines are manufactured, tested, controlled and released.
GDP: how medicines remain controlled once they move through the licensed supply chain.
That distinction matters. A batch can be manufactured correctly and still become a patient risk if storage, transport, traceability, packaging control, recall execution or trading-partner oversight breaks down.
The main theme this week is lifecycle control. Recent signals include packaging errors, contamination risks, sterile manufacturing concerns, supply shortages, unlicensed medicine distribution and the continuing importance of authorised trading partners.
This newsletter is educational. It supports awareness, discussion and professional development. It does not replace site-specific procedures, formal training, Pharmaceutical Quality Systems, Quality review, Responsible Person judgement, Qualified Person decisions, or regulatory advice.
FROM HELP ME GxP
The channel is moving from Help Me GMP into the broader Help Me GxP space.
At the time of this review, the YouTube URL still resolves under @HelpMeGMP, and the visible channel wording still carries Help Me GMP branding. The direction of travel is now wider: GMP, GDP, supply-chain integrity and practical compliance education.
That is an important shift.
GMP and GDP are not separate worlds. They are connected parts of the same patient-protection system.
Manufacturing control has to link into supplier qualification, warehouse control, transport conditions, returns, complaints, recalls, shortages and supply-chain integrity.
Help Me GxP / Help Me GMP channel:
https://www.youtube.com/@HelpMeGMP
NEWS IN PHARMA
1. UK: MHRA authorises rilzabrutinib for adults with immune thrombocytopenia
The MHRA granted a marketing authorisation for rilzabrutinib, also known as Wayrilz, for adults with immune thrombocytopenia where prior treatments have not worked well enough.
Why it matters for GxP: New authorisations are not only clinical or regulatory milestones. Once a medicine is authorised, continued confidence depends on manufacturing control, product quality, distribution, pharmacovigilance, defect reporting and supply oversight.
2. EU: EMA CHMP May 2026 highlights include eight new medicines recommended for approval
EMA's human medicines committee recommended eight new medicines for approval at its May 2026 meeting. The committee also recommended extensions of therapeutic indication for already authorised medicines.
Why it matters for GxP: Approval recommendations eventually translate into operational responsibility. Manufacturing sites, marketing authorisation holders, contract organisations and distributors all need systems that can support lifecycle control after authorisation.
3. EU: First oral GLP-1 formulation for weight management recommended as extension to Wegovy authorisation
The CHMP recommended an extension to the marketing authorisation for Wegovy to add a daily oral tablet as an alternative formulation to weekly subcutaneous injections.
Why it matters for GxP: A new formulation or presentation creates quality-system questions around process control, specifications, stability, packaging, patient information, supply planning and distribution.
4. EU: EMA Quality of Medicines Q&A Part 2 updated
EMA's Quality of Medicines Q&A Part 2 was updated on 29 May 2026, with the update history identifying a change to the section on reduced testing of incoming starting materials.
Why it matters for GxP: Reduced testing is never just a testing shortcut. It depends on justified supplier qualification, historical evidence, material risk, change control, specification control and continued monitoring.
NEWS IN DISTRO
1. UK: MHRA heatwave advice reinforces the importance of medicine storage conditions
The MHRA issued public advice on protecting medicines during hot weather, including avoiding storage in hot cars, bags or direct sunlight, and paying particular attention to medicines that require refrigeration.
Why it matters for GDP: Although this is public safety advice rather than GDP guidance, the principle is directly relevant to distribution: medicines must be stored and handled under suitable conditions. Temperature exposure is not just a logistics issue. It can become a product-quality and patient-safety issue.
2. EU: EMA lists Novo Nordisk human insulin shortage as ongoing
EMA lists the shortage status for several Novo Nordisk human insulin presentations as ongoing. EMA states that Novo Nordisk has decided to stop marketing some selected insulin presentations for commercial reasons, and that the decision is not related to a quality defect or safety issue.
Why it matters for GDP: Not every supply disruption is caused by a defect, but every supply disruption requires controlled communication, traceability, alternative-supply assessment and patient-risk management.
3. EU: EMA marks Champix shortage as resolved
EMA updated the Champix shortage page on 28 May 2026 and lists the shortage status as resolved.
Why it matters for GDP: Resolved shortages still offer learning. Supply-chain teams should ask whether stock visibility, escalation routes, alternative supply decisions and patient-facing communication worked as intended.
Source: https://www.ema.europa.eu/en/medicines/human/shortages/champix
GMP / GDP REGULATORY NEWS
1. UK: MHRA GMP and GDP inspection expectations remain the baseline
For this relaunch edition, it is useful to restate the baseline. MHRA guidance explains that GMP is the minimum standard a medicines manufacturer must meet, and that GDP requires medicines to be obtained from the licensed supply chain and consistently stored, transported and handled under suitable conditions.
Why it matters: This is the bridge between the old GMP-only newsletter and the new GxP format. Manufacturing and distribution are both inspection-facing, risk-based systems.
Source: https://www.gov.uk/guidance/good-manufacturing-practice-and-good-distribution-practice
2. US: FDA warning letter to Sato Pharmaceutical Co., Ltd. highlights sterile manufacturing and aseptic process control
FDA issued a warning letter dated 18 May 2026 citing significant cGMP violations for finished pharmaceuticals. The letter includes concerns around procedures designed to prevent microbiological contamination of products purporting to be sterile, aseptic process validation, ISO 5 design, airflow protection, media fill failures, stability methods and microbiological testing.
Why it matters: Sterile manufacturing failures are rarely isolated technical issues. They usually point to weaknesses in design, contamination control strategy, validation, environmental control, intervention control, training and Quality oversight.
3. US: FDA warning letter to Alchymars ICM SM Private Limited highlights API cGMP, maintenance and import risk
FDA issued a warning letter dated 21 May 2026 following inspection of an API manufacturing facility. The letter cites significant deviations from cGMP for active pharmaceutical ingredients, including equipment maintenance concerns. FDA also states that all drugs and drug products offered for import into the United States from the firm were placed on Import Alert 66-40 on 19 May 2026.
Why it matters: API control is part of the finished product control story. Supplier qualification, incoming material control and supply-chain risk assessments need to consider whether API manufacturers can demonstrate sustained control, not just provide paperwork.
4. US: DSCSA remains a key supply-chain integrity framework
FDA's DSCSA page explains that the framework supports an interoperable, electronic way to identify and trace certain prescription drugs at package level as they move through the US supply chain.
Why it matters for GDP: Serialisation, traceability, authorised trading partners and rapid response to suspect or illegitimate product are central to modern supply-chain control.
Source: https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa
5. US: FDA continues to emphasise authorised wholesale distributors and third-party logistics providers
FDA states that prescription drugs should only be purchased from wholesale drug distributors with a valid licence, and that third-party logistics providers must also be authorised where applicable.
Why it matters for GDP: Authorised trading-partner checks are not admin. They are one of the basic controls preventing counterfeit, stolen, diverted or otherwise illegitimate medicines entering the supply chain.
PHARMA RECALLS AND QUALITY DEFECTS
Note for this relaunch edition: The normal newsletter will use a fortnightly window. This edition uses a slightly wider catch-up window based on regulator or agency publication dates.
1. UK: Class 2 Medicines Recall - Crescent Pharma Limited, Ramipril 2.5 mg Capsules
MHRA issued a Class 2 recall for one batch of Ramipril 2.5 mg Capsules following a potential packaging error at the manufacturing site. One complaint involved a sealed carton of Ramipril 2.5 mg Capsules containing blister packs of Ramipril 10 mg Capsules. MHRA describes this as a patient, pharmacy and wholesaler level recall.
Inspection learning: Packaging operations are high-risk because a visually small error can become a dose-strength, patient-safety and traceability issue. Line clearance, reconciliation, packaging controls, complaint escalation and recall execution all become relevant.
2. UK: Class 4 Medicines Defect Notification - Fresenius Medical Care Deutschland GmbH, balance solution for peritoneal dialysis
MHRA issued a Class 4 defect notification after an error was identified in the Braille printed on the outer label. MHRA states there is no product quality issue and that the affected batches will not be recalled.
Inspection learning: Not every defect leads to recall, but labelling and accessibility errors still matter. The Pharmaceutical Quality System needs a clear route for assessing patient impact, user risk, batch scope, communication and whether corrective action is required.
3. US: FDA-posted company announcement - Sun Pharmaceutical Industries recall of DOXOrubicin Hydrochloride Liposome Injection
FDA posted a company recall announcement for one batch of DOXOrubicin Hydrochloride Liposome Injection 50 mg / 25 mL due to the potential presence of glass particles.
Inspection learning: Visible and sub-visible particulate control links back to container closure, glass handling, visual inspection, process control, deviation investigation, CAPA and market action decision-making.
4. US: FDA-posted company announcement - Pharmacal recall of MG217 Multi-Symptom Treatment Cream and Skin Protectant Eczema Cream
FDA posted a company recall announcement for one lot of MG217 cream due to microbial contamination with Staphylococcus aureus.
Inspection learning: Microbial contamination in a topical product is a reminder that contamination control is not only an aseptic manufacturing concern. Formulation, preservative effectiveness, raw materials, water, equipment cleaning, bioburden control and environmental controls can all be relevant.
GDP / SUPPLY-CHAIN SIGNALS
There is not a single global category called a GDP recall in the same way people often talk about medicine recalls.
For GDP, the closest public signals are things like wholesale authorisation changes, GDP non-compliance, illegitimate or suspect product notifications, falsified or unlicensed medicines, pharmacy or wholesaler-level recall actions, shortages, import alerts, temperature-control issues and supply-chain enforcement activity.
1. UK: MHRA reports largest ever seizure of unlicensed weight loss medicines
MHRA reported arrests after a raid recovered around 12,000 doses of unlicensed weight loss medicines. The property was believed to have been used for large-scale manufacture, assembly and distribution of unlicensed weight loss medicines, including retatrutide, tirzepatide and peptide products.
GDP learning: Supply-chain integrity is not only about paperwork. It is also about preventing unauthorised, falsified or illegally supplied medicines from reaching patients.
2. UK: Ramipril recall reached patient, pharmacy and wholesaler level
The Ramipril Class 2 recall required impacted stock to stop being supplied immediately, remaining stock to be quarantined and returned through approved processes, and patient contact where traceability information was available.
GDP learning: Recall effectiveness depends on distribution traceability. If you cannot identify where stock went, patient communication becomes slower and less targeted.
3. US: FDA import alert linked to Alchymars cGMP warning letter
FDA stated that all drugs and drug products offered for import into the United States from Alchymars were placed on Import Alert 66-40 on 19 May 2026.
GDP learning: A manufacturer's GMP status can become a supply-chain risk. Import status, supplier qualification, alternative sourcing and product availability should be connected in the quality risk assessment.
4. US: FDA-posted company announcement - undeclared pharmaceutical ingredients in a dietary supplement
FDA posted a company announcement for a voluntary nationwide recall of WAP Sensual Enhancement Capsules after FDA analysis found undeclared sildenafil, tadalafil and flibanserin.
GDP learning: This is not a licensed medicine recall, so it should not be presented as one. It is a supply-chain integrity and patient-safety signal because hidden active pharmaceutical ingredients create serious risk outside the regulated medicines pathway.
5. EU: Insulin shortage monitoring continues through EMA shortage mechanisms
EMA states that its shortages structures are monitoring the Novo Nordisk insulin supply situation and engaging with the marketing authorisation holder and stakeholders to mitigate the impact of the planned discontinuations.
GDP learning: Shortages are not only commercial events. They require controlled communication, governance, impact assessment and patient-focused decision-making.
UPCOMING CONFERENCES AND TRAINING
1. EMA Product Management Service information day 2026
Date: 9 June 2026
Location: Online / EMA, Amsterdam
Why it matters: Product data quality is becoming increasingly important across regulatory operations, supply chain, pharmacovigilance and lifecycle management. Poor data creates downstream risk.
Source: https://www.ema.europa.eu/en/events/product-management-service-pms-information-day-2026
2. FDA CDER SBIA Learn
FDA's SBIA Learn page lists training resources, webinars, recordings, online courses, newsletters, podcasts and upcoming events. The page includes a workshop dated 11 June 2026 on bioequivalence challenges for patient-centric oral formulations.
Why it matters: Official training pages are useful for regulatory affairs, QA, CMC, manufacturing and supply-chain teams who need to keep current with FDA expectations.
AUDIT READINESS TIP
Theme: Trading-partner qualification is a GDP inspection trigger.
A strong GDP system does not just ask:
Did the product arrive?
It asks:
• Was the supplier authorised?
• Was the customer authorised?
• Was the transport route controlled?
• Were storage conditions maintained?
• Was there evidence of temperature control where required?
• Were returns assessed before any decision to restock?
• Could the batch be traced quickly if a recall was issued?
• Were falsified, stolen, diverted or suspect product risks considered?
• Was the Responsible Person involved where required?
Practical checks for your next internal audit:
• Can you show a current approved supplier and customer list?
• Can you prove that each wholesaler, broker, distributor or logistics provider is authorised for the activity they perform?
• Are WDA, GDP certificate, licence or state-authorisation checks documented and periodically reviewed?
• Do your checks cover scope, not just company name?
• Are temperature requirements defined before shipment, not after a deviation?
• Are transport lanes, couriers and storage locations assessed for risk?
• Can staff explain what to do if they suspect falsified, diverted, stolen or illegitimate product?
• Can you trace one batch from receipt to onward supply quickly and accurately?
A weak supplier or customer approval process is not just a documentation gap. It is a supply-chain vulnerability.
GxP FACT
GDP is not simply warehouse GMP.
MHRA describes GDP as requiring medicines to be obtained from the licensed supply chain and to be consistently stored, transported and handled under suitable conditions, as required by the marketing authorisation or product specification.
That means GDP is a patient-safety system.
It protects the quality that GMP created.
Source: https://www.gov.uk/guidance/good-manufacturing-practice-and-good-distribution-practice
CALL TO ACTION
The newsletter is back, and it is now broader.
Help Me GxP will continue to cover GMP, but we will also bring GDP and supply-chain control into the conversation because product quality does not stop at release.
If this edition is useful, share it with colleagues in QA, QC, Production, Warehouse, Distribution, Regulatory Affairs, Responsible Person teams, QPs, pharmacists, aseptic services and supply-chain roles.
For the next edition, I will return to the normal fortnightly window and continue scanning official UK, EU and US sources for GMP and GDP signals.
Follow Help Me GxP for practical, inspection-aware GMP and GDP education.
Kyle Winn / Adam Walker
Help Me GxP
WinnPharma | PharmaQP | W2 Cleanroom Consulting
#GxP #GMP #GDP #Pharma #QualityAssurance #MHRA #EMA #FDA #PharmaceuticalManufacturing #PharmaceuticalDistribution #SupplyChainIntegrity #InspectionReadiness #PatientSafety
Contact
Get in touch
info@w2cleanrooms.com
© 2026. All rights reserved.
Our Brands
Free GxP Training
